MedTech prospecting in France: a guide to buying signals

In standard B2B cold outreach, reply rates top out around 3% (Instantly 2026 benchmark: 3.43%). In the French hospital market, that isn’t a copywriting problem. It’s a timing problem: 97% of the facilities you contact simply aren’t buying when your email lands.

High-performing MedTech prospecting in France doesn’t start from a cold list. It starts from a public buying signal that has already been issued: a tender in BOAMP (France’s official public procurement bulletin), an equipment authorization from an ARS (regional health agency), a certification visit from the HAS (France’s National Authority for Health). Reach a facility at the moment it is making a decision, and reply rates climb from 2 to 3% to between 10 and 15%.

This guide covers why generic tools fail in this market, which public sources reveal a buyer with active intent, how to turn a signal into a meeting, and which MedTech companies the method works for (and which it doesn’t).

Why aren’t generic prospecting tools enough for French MedTech?

Generic prospecting tools (Sales Navigator, Apollo, ZoomInfo) cover LinkedIn and company databases. They don’t cover healthcare professionals, public tenders, or the regulatory signals that CE marking, EUDAMED, and the ANSM make public. Eight categories of healthcare sources stay invisible to these stacks: RPPS, BOAMP, HAS, ARS, FINESS, GHT, PMSI, and industry certifications. That is exactly where buying signals live in the French hospital market. Contact enrichment databases hit the same wall: see the hospital data Apollo, Lusha, and ZoomInfo are missing.

The RPPS (France’s national registry of healthcare professionals) lists more than 1.8 million practitioners, with their specialty, place of practice, and status. A large share of them, hospital physicians in particular, are absent from LinkedIn or barely active there. A vascular surgeon at a CHU (university hospital) won’t necessarily have an up-to-date profile. In healthcare, LinkedIn should always be cross-checked against the RPPS, never used on its own. Read as a MedTech targeting engine, the RPPS segments this population by specialty, facility, and region. That cross-check is precisely what lets you launch a MedTech product in a specialty without a prospect database, rebuilding the target from the registries instead of buying a list.

The real gap isn’t in LinkedIn or Crunchbase data, which any outbound agency can access. This structural gap is why a generalist outbound agency stays blind to the French hospital market. That data can be bought, but a purchased healthcare contact database starts depreciating on day one. The lasting edge comes from reading the healthcare, regulatory, and public procurement sources that generic stacks never integrate:

This coverage is a moat: it is specific to the French market and requires expert interpretation. It is what makes reverse prospecting possible, and it is also what separates a useful project from a generic tool that changes nothing: human intelligence, not technology, is what makes an AI project succeed.

What is reverse prospecting in the hospital market?

Reverse prospecting flips the starting question. Instead of asking “Who can I sell to?” it asks “Who already needs what I sell?” A hospital preparing a purchase announces it publicly: it publishes a tender, renews an authorization, appoints a purchasing lead. Contacting that facility at that exact moment lifts reply rates from 2 to 3% to between 10 and 15%. Agify built its MedTech method on this principle.

When a hospital needs new equipment, it doesn’t wait for a sales rep’s email. It acts, and its actions are public. Those events say something precise: this facility is making a purchasing decision in an identifiable category.

That shift changes three things:

• Reply rate, from 2 to 3% to between 10 and 15%.
• Meeting quality: the prospect already has context and doesn’t need convincing that the problem exists.
• Sales workload: the ratio flips, from 80% prospecting / 20% selling to 80% selling / 20% signal qualification.

When you call someone because they just published a tender in your category, you’re no longer a cold caller. You’re the person who knew. The prospect doesn’t wonder why you’re calling; they wonder how you can help. It’s also why generic cold email is dead in 2026: what earns you the right to reach out is no longer the template, it’s the timing of the signal. The five steps of this approach and the conditions for fit are laid out in the guide to reverse prospecting.

Which public sources reveal a hospital buying signal?

Six public sources hold the most reliable buying signals in the French hospital market. BOAMP publishes tenders (documented purchase intent). The ARS publishes heavy equipment authorizations (approved budget). The HAS exposes certifications and their deadlines (regulatory pressure). Hospimedia and LinkedIn flag decision-maker appointments. BODACC (France’s official bulletin of company announcements) tracks governance changes. The PMSI quantifies activity by facility. All of them are public and legal to use.

The FINESS code (from France’s national registry of healthcare facilities) is the pivot key: it links a facility to every other registry (BOAMP, ARS, HAS, PMSI). That is what turns an isolated signal into a complete file: the facility, its decision-maker, its budget context, its purchasing history. A single BOAMP notice actually carries six readable categories of buying signals, from the named buyer all the way to the award notice that identifies the incumbent competitor. You still have to catch that notice: monitoring BOAMP by hand lets some of them slip through, for lack of continuity and coverage by CPV code.

On compliance, these sources are public and using them falls under legitimate interest (GDPR, Article 6(1)(f)), provided you respect the right to object. Building prospecting files from public data is legal. Conversely, phone coverage advertised at 100% signals data collected outside that framework.

If you want to know which signals you can actually use in your specific market, that is exactly what we cover in a scoping call: a working session that translates your product catalog into events to monitor.

How do you turn a public signal into a sales meeting?

Turning a signal into a meeting takes five steps. First, a workshop defines the events that, in the seller’s specific context, point to a buyer. Next, AI agents monitor the sources continuously. Each detected signal is qualified and scored against the ICP, decision-maker identification, and freshness (a signal older than three weeks loses its value). A contextual message references the specific event. The sales rep only receives prospects who have replied. That is how AgifyMD’s Radar and Outbound modules work.

1. Defining the signals. A 90-minute workshop with the head of sales identifies the outside events that, in their context, point to a buyer with active intent. The signal isn’t the same for an MRI manufacturer and an operating room software vendor.

2. Continuous monitoring. Agents monitor the configured public sources. When a signal matches the ICP (facility type, geography, specialty), it surfaces automatically.

3. Qualification and scoring. Every signal gets a score. Top priority goes to cases where the facility fits the ICP, the decision-maker can be identified (by cross-referencing the RPPS, LinkedIn, and Hospimedia), and the signal is recent. A signal’s typical half-life is 7 to 21 days: a six-month-old signal is dead.

4. Contextual message. The message references the specific event, not a generic pitch:

“I saw that your department recently published a tender for [category]. We work with several university hospitals on this.”

5. Sales handoff. The rep only receives confirmed meetings or prospects who replied positively. They stop prospecting and start selling.

The contextual message can also strengthen that first touch by delivering a sample of value: that’s the logic behind Big Fast Value, which delivers proof before any pitch.

What does signal-based MedTech prospecting look like in practice?

In practice, the method produces qualified databases at scale. For a French medical imaging MedTech company, cross-referencing more than ten sources made it possible, in six weeks, to keep only the truly qualified European radiologists. For a French healthcare messaging platform, 4,342 clinical facilities were mapped in nine days using HAS data.

Medical imaging: qualified radiologists across eight countries. A French imaging MedTech company had 15 sales reps across 8 countries, each with their own Excel lists and 30 to 45 minutes of manual research before every contact. Cross-referencing more than ten sources (RPPS, PubMed, ARS, BOAMP, HAS, FINESS, BODACC) produced a database of qualified prospects, segmented by region. Prep time per meeting dropped from 30 to 45 minutes to a few minutes. The full walkthrough, from raw database to cleaned-up CRM, is in the radiologist qualification case study.

“We can target exactly the people we want to reach: lists of 5 to 10 physicians, 3T MRI as a criterion, a small, tightly targeted campaign.” a member of the sales team, feedback session

Healthcare messaging: 4,342 facilities in nine days. A French healthcare messaging platform wanted to give its sales reps a complete view of private clinics. Scraping the HAS quality overview delivered 4,342 facilities with their FINESS code, certification status, and scores, plus 9,000 anesthesiologists and nurse managers, sorted into three tiers (hot, warm, cold). One signal proved especially sharp: a facility certified with conditions is a priority target, because it is preparing to come into compliance. That reading is developed in reading HAS certification as a buying signal, and the full mapping walkthrough is in the case study of 4,342 HAS clinics targeted in nine days.

Radiology conference: 64.7% of messages read. For a radiology KOL organizing a European conference, a LinkedIn campaign targeting senior radiologists in six countries got 64.7% of messages read and an 18.8% reply rate on 797 messages, 825 connections out of 2,427 radiologists contacted (34%), and 0 negative signals (no bounces, no unsubscribes). The campaign walkthrough and the comparison with LinkedIn benchmarks are in this case study on prospecting physicians on LinkedIn. On site, that preparation only pays off if you avoid what you should never do at a conference booth.

Imaging MedTech: 10,000+ leads across 18 countries in 8 days. For a French medical imaging MedTech company, the same structured-database principle was rolled out at European scale: more than 10,000 qualified medical contacts delivered in 8 days, covering 18 countries, organized into four distinct groups (heads of department across all specialties, innovation directors, biomedical engineers, MedTech manufacturers), and enriched with each profile’s preferred language. The asset fed three successive campaigns, from the ECR 2026 congress to the France heads-of-department wave. The full walkthrough is in this case study on building European medical leads in 8 days.

What the four cases have in common: performance doesn’t come from sending volume, it comes from targeting relevance. The message arrives at the right time, to the right person, with the right context.

Which MedTech companies does signal-based prospecting work for?

Signal-based prospecting works when four conditions are met: a sales cycle of 3 to 24 months, an average deal size above €10,000, several stakeholders to win over, and a product whose adoption depends on a regulatory or budget context. It isn’t a fit for B2C, very low-ticket sales, or markets with no usable public signals. A signal isn’t intent: a tender may already be awarded in all but name. These conditions aren’t unique to healthcare: a tech recruiting firm, with a long cycle and public signals to work from (funding rounds, job posting volumes), checks the same boxes, as our case study on activating a dormant lead database shows.

A long cycle leaves time to act on an intent signal. A high deal value justifies the research cost. Multiple stakeholders (clinician, buyer, IT department) are exactly what public sources help untangle. And a product shaped by regulation lines up with ARS and HAS signals.

Conversely, the method doesn’t suit B2C sales, standard products with short cycles, or markets where no public source exposes signals. In those cases, you need to add segment-level personalization, turning a truth common to the profession into a credible observation with the five cold reading patterns, then humanizing the message with voluntary disclosure.

Three honest limits are worth stating. A signal isn’t intent: a published tender may be a captive one, already awarded in all but name, which is why it pays to spot a BOAMP tender before the specifications are written. Signals have a short half-life, so monitoring has to be continuous. And the research cost per signal rises with the level of personalization: ROI is measured at the campaign level, not the individual lead. That is the whole point of the 4-tier hierarchy for personalizing at scale, which reserves deep research for the accounts that justify it.

Frequently asked questions

Is prospecting from public sources GDPR-compliant?

Yes. The RPPS, BOAMP, the HAS, the ARS, and the other registries mentioned are public sources. Using them for B2B prospecting falls under legitimate interest (GDPR, Article 6(1)(f)), provided you respect the data subjects’ right to object. The data can be used legally.

How is reverse prospecting different from inbound?

The rep still goes to the prospect, so it isn’t inbound. The difference from standard cold outreach is timing: instead of contacting a cold list at random, you contact a facility that has issued a recent intent signal. Timing becomes deterministic instead of left to chance.

How long does a buying signal stay usable?

A signal’s typical half-life is 7 to 21 days. Beyond that, its value drops fast: a tender whose deadline has passed or an appointment more than three months old no longer opens a window of opportunity. Monitoring has to be continuous and the pipeline responsive.

Should you drop Sales Navigator?

No. The two approaches complement each other. Sales Navigator identifies who exists on LinkedIn. Signal-based prospecting tells you when and why to contact a target, drawing on the healthcare sources Sales Navigator doesn’t cover. One handles sourcing, the other timing. How they layer together is detailed in why Sales Navigator and a signal agent complement each other in MedTech, and the inventory of eight hospital buying signals Sales Navigator can’t see spells out, source by source, what it misses.

What volume of qualified leads can you expect?

Volume depends on the size of the addressable market and how often signals occur. Observed examples range from a few thousand to more than ten thousand qualified leads, depending on geographic scope and specialty. Qualification, not raw volume, is the metric to track.

Conclusion

MedTech prospecting in France isn’t won on copywriting; it’s won on timing. Three takeaways: generic tools can’t see the eight categories of healthcare sources where buying signals live; reverse prospecting lifts reply rates from 2 to 3% to between 10 and 15% by reaching a facility at the moment it decides; and the method comes down to five steps, from signals defined in a workshop to the meeting handed off to the sales rep.

What’s left is figuring out which signals matter in your specific market. Let’s talk through your case in 30 minutes: together we’ll identify the public sources relevant to your catalog and how to turn them into pipeline.

---

Agify deploys autonomous AI prospecting agents inside B2B sales teams, with a specialization in the French MedTech market and its public healthcare sources.